Skip to main navigation Skip to search Skip to main content

Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population

  • Ivan Cherrez-Ojeda
  • , Arturo Cortés-Telles
  • , Laura Gochicoa-Rangel
  • , Génesis Camacho-Leon
  • , Hans Mautong
  • , Karla Robles-Velasco
  • , Marco Faytong-Haro
  • Respiralab Research Group
  • Hospital Regional de Alta Especialidad de Yucatán
  • Instituto Nacional de Enfermedades Respiratorias
  • Larkin Community Hospital
  • Universidad Espíritu Santo, Ecuador
  • Pennsylvania State University
  • Ecuadorian Development Research Lab

Research output: Contribution to journal › Comment/debate

12 Scopus citations

Abstract

This commentary aims to highlight some of the major issues (with possible solutions) that the Latin American region is currently dealing with in managing post-COVID-19 pulmonary fibrosis. Overall, there is little evidence for successful long-term COVID-19 follow-up treatment. The lack of knowledge regarding proper treatment is exacerbated in Latin America by a general lack of resources devoted to healthcare, and a lack of availability and access to multidisciplinary teams. The discussion suggests that better infrastructure (primarily multicenter cohorts of COVID-19 survivors) and well-designed studies are required to develop scientific knowledge to improve treatment for the increasing prevalence of pulmonary fibrosis in Latin America.

Original languageEnglish
Article number1393
JournalJournal of Personalized Medicine
Volume12
Issue number9
DOIs
StatePublished - Sep 2022

Keywords

  • COVID-19
  • Latin America
  • SARS-CoV-2
  • pandemic
  • pulmonary fibrosis

Fingerprint

Dive into the research topics of 'Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population'. Together they form a unique fingerprint.

Cite this